KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) EBT Margin (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed EBT Margin for 9 consecutive years, with 61.0% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 8076.0% year-over-year to 61.0%, compared with a TTM value of 30.56% through Dec 2025, up 4986.0%, and an annual FY2025 reading of 30.56%, up 4986.0% over the prior year.
  • EBT Margin was 61.0% for Q4 2025 at Biocryst Pharmaceuticals, up from 7.61% in the prior quarter.
  • Across five years, EBT Margin topped out at 61.0% in Q4 2025 and bottomed at 59.23% in Q4 2023.
  • Average EBT Margin over 3 years is 7.39%, with a median of 11.43% recorded in 2024.
  • Peak annual rise in EBT Margin hit 8076bps in 2025, while the deepest fall reached 1541bps in 2025.
  • Year by year, EBT Margin stood at 59.23% in 2023, then surged by 67bps to 19.76% in 2024, then skyrocketed by 409bps to 61.0% in 2025.
  • Business Quant data shows EBT Margin for BCRX at 61.0% in Q4 2025, 7.61% in Q3 2025, and 3.97% in Q2 2025.